Marshall Wace’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Marshall Wace’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,559	Closed	-$1.71M	–	3593
2025 Q4	$1.71M	Buy	2,559 +1,509	+144%	+$759K	﹤0.01%	1652
2025 Q3	$342K	Buy	+1,050	New	+$350K	﹤0.01%	2376
2022 Q3	–	Sell	-82	Closed	-$36K	–	3712
2022 Q2	$36K	Buy	+82	New	+$58K	﹤0.01%	3342
2021 Q4	–	Sell	-304	Closed	-$5.56M	–	4208
2021 Q3	$5.56M	Buy	304 +111	+58%	+$1.77M	0.02%	880
2021 Q2	$2.05M	Buy	+193	New	+$1.62M	0.01%	1398
2021 Q1	–	Sell	-178	Closed	-$987K	–	2789
2020 Q4	$987K	Sell	178 -16	-8%	-$142K	0.01%	1219
2020 Q3	$1.94M	Buy	194 +115	+146%	+$1.05M	0.01%	815
2020 Q2	$735K	Buy	79 +63	+394%	+$577K	0.01%	1087
2020 Q1	$150K	Buy	+16	New	+$158K	﹤0.01%	1242

Other funds holding IRLA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Marshall Wace's IRLA Position: Q1 2026 in Review

Marshall Wace sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2026, closing a stake of 2,559 shares — an estimated $1.71M sold.

Marshall Wace first reported a position in IRLA in Q1 2020 and held it in 9 quarters. The position peaked at $5.56M in Q3 2021. 43 funds tracked by Wall St. Rank hold IRLA as of Q1 2026.

Marshall Wace reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 2,559 IRulya Therapeutics Inc. Common Stock shares in Q1 2026, an estimated $1.71M.
Marshall Wace first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2020 and held it in 9 quarters.
Marshall Wace's IRulya Therapeutics Inc. Common Stock position peaked at $5.56M in Q3 2021.
43 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.